fludarabine has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 25 (56.82) | 29.6817 |
| 2010's | 14 (31.82) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Doorduijn, JK; Dreyling, MH; Feugier, P; Geisler, CH; Hermine, O; Hoster, E; Kaiser, F; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Pott, C; Ribrag, V; Salles, G; Schmidt, C; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Walewski, J; Zijlstra, JM | 1 |
| Beitinjaneh, A; Flinn, IW; Fung, H; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Jain, RK; Kersten, MJ; Locke, FL; McSweeney, PA; Miklos, DB; Milpied, N; Munoz, J; Pagel, JM; Peng, W; Rao, AV; Reagan, PM; Rossi, JM; Timmerman, JM; Topp, MS; Wang, M; Zheng, L | 1 |
| de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X | 1 |
| Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL | 1 |
| Appelbaum, FR; Cassaday, RD; Fisher, DR; Gooley, TA; Gopal, AK; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Shields, A | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Alam, M; Arrey, TN; Doktorova, E; Klanova, M; Klener, P; Lorkova, L; Maswabi, B; Petrak, J; Pospisilova, J; Scigelova, M; Vit, O; Vockova, P | 1 |
| Bolam, S; Follows, G; Gambell, J; Hillmen, P; Jack, A; Johnson, PW; Johnson, S; Kirkwood, AA; Kruger, A; Linch, D; Pocock, C; Rule, S; Seymour, JF; Smith, P; Toncheva, M; Walewski, J | 1 |
| Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M | 1 |
| Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH | 1 |
| Cupelli, L; de Fabritiis, P; Dentamaro, T; Giovannini, M; Niscola, P; Palumbo, R; Perrotti, AP; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Eve, HE; Linch, D; Qian, W; Ross, M; Rule, SA; Seymour, JF; Smith, P; Stevens, L | 1 |
| Eve, HE; Rule, SA; Seymour, JF | 1 |
| Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Eve, HE; Gambell, J; Qian, W; Rule, SA; Smith, P | 1 |
| Buda, G; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| Cattaneo, R; Frenzke, ME; Johnston, PB; Miest, T; Ungerechts, G; Yaiw, KC | 1 |
| Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M | 1 |
| Elonen, E; Honkanen, T; Jantunen, E; Jyrkkiö, S; Karjalainen-Lindsberg, ML; Kuittinen, O; Lehto, M; Mikkola, M; Poikonen, E; Räsänen, A; Räty, R; Rauhala, A; Rimpiläinen, J; Siitonen, S; Suominen, M; Vapaatalo, M | 1 |
| André, M; Bouabdallah, R; Coiffier, B; Di Raimondo, F; Doorduijn, JK; Dreyling, MH; Feugier, P; Forstpointner, R; Geisler, CH; Hallek, M; Hermine, O; Hiddemann, W; Hoster, E; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Kremers, S; Lepeu, G; Lugtenburg, PJ; Macro, M; Pfreundschuh, M; Procházka, V; Ribrag, V; Sanhes, L; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Uppenkamp, M; Vehling-Kaiser, U; Walewski, J; Zijlstra, JM | 1 |
| Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Dreyling, M; Hiddemann, W; Unterhalt, M | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Johnson, SA | 1 |
| Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Agura, E; Chauncey, T; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; Pulsipher, M; Sandmaier, BM; Storb, R; Storer, BE; Stuart, MJ | 1 |
| Dreyling, M; Hiddemann, W; Lenz, G | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; Espinet, B; Ferrer, A; López-Guillermo, A; Marcé, S; Montserrat, E; Solé, F; Villamor, N | 1 |
| Hillmen, P; Johnson, SA; Owen, RG; Rule, SA; Seymour, JF; Thomas, DW; Wolf, MM | 1 |
| Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L | 1 |
| Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Hanamura, A; Hayakawa, M; Naito, K | 1 |
| Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Aitini, E; Battista, R; Bendandi, M; Bocchia, M; Cellini, C; De Renzo, A; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Magagnoli, M; Moretti, L; Ronconi, F; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Ogura, M | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
5 review(s) available for fludarabine and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine | 2009 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Vidarabine | 2004 |
[Mantle cell lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Rituximab; Vidarabine | 2001 |
25 trial(s) available for fludarabine and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Time; Vidarabine; Vincristine | 2020 |
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Infusions, Intravenous; Leukapheresis; Lymphoma, Mantle-Cell; Middle Aged; Receptors, Chimeric Antigen; Recurrence; Survival Analysis; T-Lymphocytes; Vidarabine | 2020 |
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine | 2021 |
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vidarabine | 2021 |
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Transplantation, Autologous; Vidarabine | 2014 |
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Opportunistic Infections; Rituximab; Survival Analysis; Vidarabine | 2016 |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2016 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat | 2016 |
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2009 |
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Rituximab; Severity of Illness Index; Survival; Treatment Outcome; Vidarabine | 2009 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2011 |
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Treatment of older patients with mantle-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Rituximab; Survival Rate; Vidarabine; Vincristine | 2012 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2004 |
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Topics: Adult; Aged; Combined Modality Therapy; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine | 2006 |
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Survival Rate; Treatment Outcome; Vidarabine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
15 other study(ies) available for fludarabine and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Humans; Isotope Labeling; Lymphoma, Mantle-Cell; Male; Proteomics; Tandem Mass Spectrometry; Tumor Cells, Cultured; Vidarabine | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Renal Dialysis; Transplantation Conditioning; Vidarabine | 2009 |
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine | 2010 |
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; Cells, Cultured; Chlorocebus aethiops; Cyclophosphamide; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Measles virus; Mice; Mice, SCID; Molecular Targeted Therapy; Oncolytic Viruses; Salvage Therapy; Tumor Burden; Vero Cells; Vidarabine; Xenograft Model Antitumor Assays | 2010 |
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine | 2002 |
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Cyclophosphamide; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Mitoxantrone; Proteins; Reactive Oxygen Species; Staurosporine; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2005 |
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2006 |
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Rituximab; Vidarabine; Vincristine | 2005 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |